See more : Futebol Clube do Porto – Futebol, S.A.D. (FCP.LS) Income Statement Analysis – Financial Results
Complete financial analysis of Microbot Medical Inc. (MBOT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Microbot Medical Inc., a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.
You may be interested
- NightDragon Acquisition Corp. (NDACU) Income Statement Analysis – Financial Results
- F5, Inc. (0IL6.L) Income Statement Analysis – Financial Results
- Mallard Acquisition Corp. (MACU) Income Statement Analysis – Financial Results
- National Bank of Canada (NBKCF) Income Statement Analysis – Financial Results
- Chalet Hotels Limited (CHALET.BO) Income Statement Analysis – Financial Results
Microbot Medical Inc. (MBOT)
Industry: Medical - Instruments & Supplies
Sector: Healthcare
Website: https://www.microbotmedical.com
About Microbot Medical Inc.
Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company, through its ViRob, TipCAT, CardioSert, and Liberty micro-robotic technologies, developing Self Cleaning Shunt for the treatment of hydrocephalus and normal pressure hydrocephalus; a disposable robot for various endovascular interventional procedures; and a multi generation pipeline portfolio. It has 42 issued/allowed patents and 23 patent applications pending worldwide. The company has a strategic collaboration agreement with Stryker Corporation for technology co-development. Microbot Medical Inc. was founded in 2010 and is based in Hingham, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 117.00K | 1.01M | 1.20M | 1.37M | 1.22M | 1.43M | 992.87K | 231.73K | 56.72K | 92.85K | 205.91K | 141.03K | 273.43K | 415.38K | 805.23K | 74.30K | 5.02M | 8.80M | 10.60M | 7.10M | 11.80M | 1.30M | 3.00M | 1.40M | 500.00K |
| Cost of Revenue | 106.00K | 102.00K | 76.00K | 68.00K | 84.00K | 54.00K | 21.00K | 10.00K | 17.00K | 0.00 | 316.00K | 263.19K | 215.00K | 168.42K | 261.44K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -2.78M | -2.05M | -2.80M | 16.50M | -1.80M | -1.50M | -1.80M | 10.30M | 7.40M | 4.70M |
| Gross Profit | -106.00K | -102.00K | -76.00K | -68.00K | -84.00K | -54.00K | -21.00K | -10.00K | 100.00K | 1.01M | 887.00K | 1.10M | 1.01M | 1.26M | 731.43K | 231.73K | 56.72K | 92.85K | 205.91K | 141.03K | 273.43K | 415.38K | 805.23K | 2.86M | 7.07M | 11.60M | -5.90M | 8.90M | 13.30M | 3.10M | -7.30M | -6.00M | -4.20M |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 85.47% | 100.00% | 73.73% | 80.76% | 82.39% | 88.20% | 73.67% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 3,845.92% | 140.75% | 131.82% | -55.66% | 125.35% | 112.71% | 238.46% | -243.33% | -428.57% | -840.00% |
| Research & Development | 5.72M | 7.74M | 6.15M | 3.40M | 3.05M | 2.52M | 1.10M | 901.00K | 27.11M | 21.50M | 20.53M | 15.85M | 19.94M | 21.02M | 19.93M | 17.81M | 19.94M | 13.60M | 8.93M | 8.76M | 6.14M | 6.40M | 8.60M | 5.98M | 9.98M | 17.70M | 0.00 | 17.10M | 14.70M | 13.50M | 0.00 | 0.00 | 0.00 |
| General & Administrative | 4.13M | 5.43M | 5.09M | 5.56M | 4.03M | 4.50M | 4.01M | 8.73M | 9.33B | 65.11 | 44.17 | 0.00 | 0.00 | 0.00 | 0.00 | 8.30M | 7.93B | 7.15B | 4.84B | 3.95B | 3.39B | 4.23B | 3.79M | 3.36M | 4.93M | 4.60M | 6.20M | 5.70M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 23.00K | 26.00K | 180.00K | -9.32B | 10.42M | 8.90M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -7.92B | -7.15B | -4.83B | -3.95B | -3.38B | -4.22B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 4.13M | 5.43M | 5.09M | 5.56M | 4.03M | 4.52M | 4.04M | 8.73M | 9.33M | 10.42M | 8.90M | 7.45M | 8.20M | 9.38M | 9.53M | 8.30M | 7.93M | 7.15M | 7.66M | 6.78M | 6.28M | 4.23M | 3.79M | 3.36M | 4.93M | 4.60M | 6.20M | 5.70M | 4.60M | 4.70M | 3.40M | 2.90M | 1.80M |
| Other Expenses | 0.00 | 120.00K | 112.00K | 130.00K | 165.00K | 205.00K | 130.00K | -180.00K | 130.00K | -46.00K | 68.00K | 33.69K | 727.27M | 53.57M | 649.61K | 866.20M | 783.02M | 709.21K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.78M | 2.05M | 2.80M | 2.10M | 1.80M | 1.50M | 1.80M | 1.50M | 800.00K | 400.00K |
| Operating Expenses | 9.86M | 13.28M | 11.36M | 9.09M | 7.24M | 7.24M | 5.27M | 9.64M | 36.45M | 31.92M | 29.43M | 23.29M | 28.14M | 30.40M | 30.11M | 26.10M | 27.86M | 21.46M | 16.59M | 15.54M | 12.42M | 10.63M | 12.39M | 12.12M | 16.96M | 25.10M | 8.30M | 24.60M | 20.80M | 20.00M | 4.90M | 3.70M | 2.20M |
| Cost & Expenses | 9.86M | 13.28M | 11.36M | 9.09M | 7.24M | 7.24M | 5.27M | 9.64M | 36.45M | 31.92M | 29.75M | 23.56M | 28.36M | 30.56M | 30.37M | 26.10M | 27.86M | 21.46M | 16.59M | 15.54M | 12.42M | 10.63M | 12.39M | 9.34M | 14.91M | 22.30M | 24.80M | 22.80M | 19.30M | 18.20M | 15.20M | 11.10M | 6.90M |
| Interest Income | 0.00 | 54.00K | 44.00 | 80.00 | 103.00 | 0.00 | 0.00 | 0.00 | 7.54K | 8.53K | 11.32K | 15.59K | 13.94K | 26.73K | 67.35K | 803.10K | 2.46M | 2.48M | 1.12M | 322.23K | 38.83K | 108.70K | 200.77K | 303.75K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 80.00K | 103.00K | 0.00 | 238.00K | 334.00K | 506.32K | 1.30M | 1.17M | 50.19K | 71.36K | 93.38K | 110.81K | 109.76K | 123.61K | 143.00K | 171.91K | 191.01K | 207.11K | 226.72K | 0.00 | 272.51K | 0.00 | 500.00K | 0.00 | 600.00K | 700.00K | 400.00K | 400.00K | 200.00K | 100.00K |
| Depreciation & Amortization | 106.00K | 102.00K | 76.00K | 68.00K | 84.00K | 54.00K | 21.00K | 10.00K | 1.13M | 1.31M | 1.06M | 991.72K | 1.21M | 1.52M | 1.69M | 1.19M | 1.17M | 1.04M | 1.44M | 1.87M | 1.01M | 402.19K | 1.89M | 2.78M | 2.05M | 2.80M | 2.10M | 1.80M | 1.50M | 1.80M | 1.50M | 800.00K | 400.00K |
| EBITDA | -10.63M | -13.18M | -11.28M | -9.02M | -7.16M | -7.19M | -5.25M | -9.63M | -897.00K | -29.66M | -24.21M | -27.45M | -20.05M | -23.63M | -25.22M | -27.79M | -23.72M | -17.76M | -10.48M | -14.10M | -11.13M | -9.81M | -9.70M | -6.48M | -7.84M | -10.70M | -12.10M | -13.90M | -6.00M | -15.10M | -10.70M | -8.90M | -6.00M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -31,291.45% | -3,052.57% | -2,637.91% | -1,545.98% | -2,702.46% | -2,212.89% | -3,029.50% | -8,966.09% | -47,746.50% | -21,219.87% | -9,056.85% | -9,551.51% | -4,080.33% | -2,352.31% | -2,189.93% | -6,180.28% | -35.76% | -136.36% | -81.13% | -232.39% | -45.76% | -1,238.46% | -356.67% | -635.71% | -1,240.00% |
| Operating Income | -9.86M | -13.28M | -11.36M | -9.09M | -7.24M | 7.24M | -5.27M | -9.64M | -36.72M | -30.91M | -28.61M | -22.55M | -27.13M | 29.36M | 29.38M | 26.74M | 28.59M | 21.37M | 16.39M | 15.40M | 12.15M | 10.21M | 11.59M | 9.27M | -9.89M | 13.50M | -14.20M | 15.70M | 7.50M | 16.90M | 12.20M | 9.70M | 6.40M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -31,384.62% | -3,054.35% | -2,377.81% | -1,648.13% | -2,222.30% | 2,057.47% | 2,958.92% | 11,538.44% | 50,405.78% | 23,016.51% | 7,958.70% | 10,919.24% | 4,442.17% | 2,458.03% | 1,438.84% | 12,470.98% | -196.94% | 153.41% | -133.96% | 221.13% | 63.56% | 1,300.00% | 406.67% | 692.86% | 1,280.00% |
| Total Other Income/Expenses | -885.00K | 113.00K | 44.00K | -80.00K | -7.00K | 4.00K | -2.32M | -28.00K | -6.00K | -31.36M | -25.63M | -6.30M | 5.81M | 4.12M | -56.40M | -55.82M | -28.59M | -40.32M | 1.82M | -2.76M | 23.76K | -10.21M | -11.59M | -9.27M | -6.05M | -13.50M | -3.50M | -15.70M | -7.50M | -16.90M | -12.20M | -9.70M | -6.40M |
| Income Before Tax | -10.74M | -13.17M | -11.31M | -9.17M | -7.25M | -7.24M | -7.59M | -9.66M | -36.41M | -32.26M | -26.44M | -28.49M | -21.33B | -25.24B | -27.03B | -29.09B | -25.02B | -18.95B | 20.09M | 15.34M | 12.17M | 10.17M | -4.02B | 7.38M | -15.94M | 14.80M | -17.70M | 18.30M | 6.90M | 17.90M | 0.00 | 0.00 | 6.60M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -31,123.08% | -3,187.85% | -2,197.76% | -2,082.76% | -1,746,808.85% | -1,769,029.18% | -2,722,049.31% | -12,552,011.82% | -44,114,809.07% | -20,407,517.50% | 9,754.91% | 10,875.51% | 4,450.86% | 2,449.13% | -499,421.53% | 9,926.20% | -317.37% | 168.18% | -166.98% | 257.75% | 58.47% | 1,376.92% | 0.00% | 0.00% | 1,320.00% |
| Income Tax Expense | 0.00 | -118.00M | -44.00K | 80.00K | 103.00K | -14.48M | 2.32M | 28.00K | -908.70K | 477.80K | -3.09M | 83.89K | -7.01M | -3.89M | -2.35M | 3.21M | -2.79M | -2.42M | -4.65M | -69.54K | 144.53K | 154.98K | -8.14M | 2.08M | 5.82M | -900.00K | 3.90M | -1.90M | 1.40M | -400.00K | 300.00K | 300.00K | 0.00 |
| Net Income | -10.74M | 104.83M | -11.27M | -9.25M | -7.35M | -7.24M | -7.59M | -9.66M | -36.42M | -32.74M | -26.44M | -28.49M | -21.33M | -25.24M | -27.03M | -29.09M | -25.02M | -18.95M | -11.74M | -15.33M | -12.29M | -10.37M | -3.45M | -11.34M | -15.71M | -12.60M | -18.10M | -13.80M | -8.90M | -16.50M | -12.50M | -10.00M | -6.40M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -31,123.93% | -3,235.28% | -2,197.76% | -2,082.76% | -1,746.76% | -1,769.03% | -2,722.05% | -12,552.01% | -44,114.81% | -20,407.52% | -5,700.61% | -10,869.93% | -4,495.03% | -2,495.34% | -428.01% | -15,264.44% | -312.81% | -143.18% | -170.75% | -194.37% | -75.42% | -1,269.23% | -416.67% | -714.29% | -1,280.00% |
| EPS | -1.05 | 14.44 | -1.59 | -1.30 | -1.72 | -2.49 | -3.48 | -10.14 | -497.22 | -860.88 | -986.42 | -1.60K | -2.44K | -3.32K | -4.13K | -5.70K | -5.08K | -4.11K | -2.99K | -5.01K | -6.21K | -6.69K | -2.51K | -9.16K | -13.61K | -11.16K | -17.49K | -14.33K | -9.51K | -24.30K | -19.35K | -20.70K | -16.45K |
| EPS Diluted | -1.05 | 14.44 | -1.59 | -1.30 | -1.72 | -2.49 | -3.48 | -10.14 | -497.22 | -860.88 | -986.42 | -1.60K | -2.44K | -3.32K | -4.13K | -5.70K | -5.08K | -4.11K | -2.99K | -5.01K | -6.21K | -6.69K | -2.38K | -9.16K | -13.58K | -11.16K | -17.49K | -14.33K | -9.51K | -24.30K | -19.35K | -20.70K | -16.45K |
| Weighted Avg Shares Out | 10.20M | 7.26M | 7.11M | 7.12M | 4.27M | 2.90M | 2.18M | 952.89K | 73.24K | 38.03K | 26.80K | 17.79K | 8.76K | 7.61K | 6.55K | 5.11K | 4.92K | 4.61K | 3.93K | 3.06K | 1.98K | 1.55K | 1.37K | 1.24K | 1.15K | 1.13K | 1.04K | 963.00 | 936.00 | 679.00 | 646.00 | 483.00 | 389.00 |
| Weighted Avg Shares Out (Dil) | 10.20M | 7.26M | 7.11M | 7.12M | 4.27M | 2.90M | 2.18M | 952.92K | 73.24K | 38.03K | 26.80K | 17.79K | 8.76K | 7.61K | 6.55K | 5.11K | 4.92K | 4.61K | 3.93K | 3.06K | 1.98K | 1.55K | 1.45K | 1.24K | 1.16K | 1.13K | 1.04K | 963.00 | 936.00 | 679.00 | 646.00 | 483.00 | 389.00 |
Microbot Medical Stock Rises After Completing ACCESS-PVI Trial
MBOT announces the successful completion of its ACCESS-PVI clinical trial for the LIBERTY Endovascular Robotic Surgical System, paving the way for FDA submission.
Microbot Medical Announces the Successful Completion of its Pivotal Human Clinical Trial; Accelerates Go-to-Market Strategy to Prepare for Commercial Launch of LIBERTY® during 2Q 2025
U.S. Food and Drug Administration (FDA) Submission Expected by end of 2024 Clinical Data to be Presented at Medical Conference in Early 2025 BRAINTREE, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative...
Microbot Medical Accelerates Patient Enrollment of its Pivotal Human Clinical Trial; Expects to Complete the Trial Earlier Than Anticipated as 80% of Patients Have Completed Follow up
Confirms the Company on Track for FDA 510(k) Submission by end of 2024 Completes All IDE required Tests and Receives Final IDE Approval from the FDA for the ACCESS-PVI Study BRAINTREE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Microbot Medical...
Microbot Medical Announces the Successful Enrollment of 50% of the Patients in its Pivotal Human Clinical Trial for the LIBERTY Endovascular Robotic Surgical System
Completion of enrollment expected in Q4 with FDA submission for commercialization anticipated by the end of 2024 Completion of enrollment expected in Q4 with FDA submission for commercialization anticipated by the end of 2024
Microbot Medical (MBOT) Inks New Phase 2 Agreement for LIBERTY
Microbot Medical (MBOT) signs a Phase 2 collaboration agreement with Corewell Health to advance remote telesurgery for endovascular procedures using LIBERTY.
Microbot Medical Signs Phase 2 Collaboration Agreement with Corewell Health to Advance Remote Telesurgery Using the LIBERTY® Endovascular Robotic System
The agreement follows the successful completion of Phase 1 which evaluated the viability of LIBERTY as a remote telesurgery platform
Microbot Medical (MBOT) Gets Quality Certification for its System
Microbot Medical (MBOT) secures ISO 13485:2016 certification for its LIBERTY Endovascular Robotic System, a milestone that streamlines European and FDA regulatory compliance for future commercialization.
Microbot Medical Receives Quality Certification to Support Future Regulatory Submissions and Commercialization
The ISO 13485 certification is a validation of the Company's robust quality system The ISO 13485 certification is a validation of the Company's robust quality system
Microbot Medical (MBOT) Inks Deal to Test Autonomous Robotics
Microbot Medical (MBOT) announces an agreement with Emory University to explore the potential of integrating robotics, procedure planning and navigation into a single autonomous system.
Microbot Medical and Emory University to Evaluate the Future Autonomous Capabilities of the LIBERTY® Endovascular Robotic Surgical System
The evaluation phase will explore the potential of integrating robotics, procedure planning and navigation into a single autonomous system The evaluation phase will explore the potential of integrating robotics, procedure planning and navigation into a single autonomous system
Source: https://incomestatements.info
Category: Stock Reports